argenx SE
ARGXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeargenx SE argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The $53.84B market capitalization puts ARGX squarely in large-cap range for its industry. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Market Cap
$53.84B
Beta
-0.02
P/E (TTM)
38.14
P/E (Fwd)
23.26
EPS (TTM)
$22.56
EPS (Fwd)
$37.00
ROE
—
ROA
—
Cash
$4.44B
Total Debt
$47.2M
Free CF
—
52W Change
52.4%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $4.44B in cash comfortably exceeding the $47.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Revenue has grown from $410.7M (2022) to $4.15B (2025), reflecting a 911% increase over the period.
ARGX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, ARGX has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing ARGX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.